Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC

(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news